FDA Fast-Tracks Knee Implant That Could Replace Surgery

Millions of people living with torn knee cartilage may soon have a new option that could save their joints and their mobility.

The FDA granted Breakthrough Device Designation to Orthonika's Total Meniscus Replacement implant, a synthetic cartilage designed to work like the real thing. The London-based company also earned a spot in the FDA's special fast-track program that helps revolutionary medical devices reach patients faster.

This matters because right now, people with badly damaged knee cartilage face a tough choice. Surgeons perform about two million meniscus removal procedures every year across the US and Europe. In more than 80% of severe cases, doctors simply remove the damaged cartilage because there's no good replacement option available.

But removing that cushioning cartilage often leads to chronic pain, limited movement, and arthritis that gets worse over time. Many patients eventually need total knee replacement surgery.

Orthonika's implant aims to fill that gap. The device mimics how natural meniscus cartilage works, absorbing shock and protecting the knee joint. Doctors can install it through small incisions using minimally invasive arthroscopic surgery, the same technique used for many knee procedures today.

Dr. Maria Kristina Bartolo, Orthonika's CEO and founding engineer, called the designation "a testament to both the unmet clinical need and the strength of our technology." She noted that no approved synthetic solution currently exists for total meniscus replacement.

The Ripple Effect

The technology could reshape treatment for one of the world's most common orthopedic injuries. By preserving joint health instead of removing damaged tissue, the implant might delay or even prevent knee replacement surgery for countless patients. That means more people staying active, working without pain, and maintaining independence as they age.

The device has already proven successful in advanced animal testing. With FDA priority review and proprietary technology backing it, Orthonika is positioning to serve a multi-billion dollar market across the US and Europe.

The company is now in final preclinical development stages, moving closer to human trials and eventual availability.

For anyone facing meniscus surgery or living with knee pain, this breakthrough represents real hope for better options ahead.